Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

NCT: NCT07871409 · NOT_YET_RECRUITING

NCT IDNCT07871409
StatusNOT_YET_RECRUITING
Start Date2026-10-28
Completion2027-09-08
SponsorAmgen (INDUSTRY)
First posted
Last updated

Brief Summary

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑